Oral · GLP-1 / GIP / glucagon triple
NA-931
3 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
3
Active
1
Recruiting
0
Completed
2
Sites
23
Countries
3
Endpoints
25
Composite endpoints
4
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
5
2
2
1
1
1
1
1
1
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06732245Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese | GLP-1 / incretin class catch-all, NA-931, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Not yet recruiting | 17 | Aug 2027 | — | |
| NCT06564753Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition | NA-931 Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 5 | Feb 2025 | — | |
| T2DMPhase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus | NA-931 Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 1 | Completed | 2 | Aug 2024 | — |